Vascular Endothelial Growth Factor C (VEGFC) Antibody
247€ (100 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Vascular Endothelial Growth Factor C (VEGFC) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx175067
tested applications
WB, IHC, IF/ICC
Description
Vascular Endothelial Growth Factor C (VEGFC) Antibody is a Mouse Monoclonal antibody against Vascular Endothelial Growth Factor C (VEGFC).
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Vascular Endothelial Growth Factor C (VEGFC) |
| Host | Mouse |
| Reactivity | Human |
| Recommended Dilution | WB: 0.01-2 µg/ml, IHC: 5-20 µg/ml, IF/ICC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | Unconjugated |
| Isotype | IgG1 Kappa |
| Purification | Purified by Protein A and Protein G affinity chromatography. |
| Size 1 | 100 µl |
| Size 2 | 200 µl |
| Size 3 | 1 ml |
| Form | Liquid |
| Tested Applications | WB, IHC, IF/ICC |
| Buffer | 0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol. |
| Availability | Shipped within 5-7 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| Alias | VRP,Flt4-L,LMPH1D,LMPHM4,Vascular endothelial growth factor-related protein |
| Background | Antibody anti-VEGFC |
| Status | RUO |
Descripción
VEGFC is primarily responsible for lymphangiogenesis, the formation of lymphatic vessels, by binding to VEGFR-3 on lymphatic endothelial cells During embryonic development and tissue repair, VEGFC promotes the sprouting and maturation of lymphatic vessels VEGFC also activates VEGFR-2 in certain contexts, contributing to angiogenesis and vascular remodeling VEGFC plays a significant role in pathological processes, including cancer metastasis, where it enhances lymphatic vessel growth and facilitates tumor cell dissemination via the lymphatic system Overexpression of VEGFC is observed in various cancers such as breast cancer, melanoma, and prostate cancer, correlating with lymph node metastasis Targeting VEGFC signaling is a promising strategy to inhibit lymphangiogenesis and reduce cancer spread while maintaining tissue fluid balance and immune cell trafficking
Related Products
Human VEGF-C (Vascular Endothelial Growth Factor C) ELISA Kit
Ver Producto
Mouse VEGFC (Vascular endothelial growth factor C) ELISA Kit
Ver Producto